126 related articles for article (PubMed ID: 34678477)
41. What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
Benoit L; Zerbib J; Koual M; Nguyen-Xuan HT; Delanoy N; Le Frère-Belda MA; Bentivegna E; Bats AS; Fournier L; Azaïs H
Gynecol Oncol; 2021 Sep; 162(3):667-673. PubMed ID: 34217542
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.
Lv X; Cui S; Zhang X; Ren C
J Gynecol Oncol; 2020 Mar; 31(2):e12. PubMed ID: 31912670
[TBL] [Abstract][Full Text] [Related]
43. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
45. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of peritoneal washing cytology in gynecologic malignancies: a controversial issue.
Binesh F; Akhavan A; Behniafard N; Zabihi S; Hosseinizadeh E
Asian Pac J Cancer Prev; 2014; 15(21):9405-10. PubMed ID: 25422232
[TBL] [Abstract][Full Text] [Related]
47. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
48. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
49. RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Bogani G; Matteucci L; Tamberi S; Ditto A; Sabatucci I; Murgia F; Arcangeli V; Maltese G; Comerci G; Stefanetti M; Sonetto C; Calareso G; Marchiano A; Chiappa V; Lorusso D; Raspagliesi F
Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():93-99. PubMed ID: 31029972
[TBL] [Abstract][Full Text] [Related]
50. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
[TBL] [Abstract][Full Text] [Related]
51. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
52. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Dahm-Kähler P; Holmberg E; Holtenman M; Rådestad AF; Borgfeldt C; Hjerpe E; Marcickiewicz J; Bjurberg M; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E; Stålberg K
Gynecol Oncol; 2021 Apr; 161(1):244-250. PubMed ID: 33581846
[TBL] [Abstract][Full Text] [Related]
53. Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer.
Angeles MA; Cabarrou B; Gil-Moreno A; Pérez-Benavente A; Spagnolo E; Rychlik A; Martínez-Gómez C; Guyon F; Zapardiel I; Querleu D; Illac C; Migliorelli F; Bétrian S; Ferron G; Hernández A; Martinez A
J Gynecol Oncol; 2021 Nov; 32(6):e78. PubMed ID: 34431252
[TBL] [Abstract][Full Text] [Related]
54. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients.
Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A
Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466
[TBL] [Abstract][Full Text] [Related]
55. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
[TBL] [Abstract][Full Text] [Related]
57. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P
Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250
[TBL] [Abstract][Full Text] [Related]
58. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
[TBL] [Abstract][Full Text] [Related]
59. Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study.
Glover O; Asher V; Bali A; Abdul S; Collins A; Phillips A
Anticancer Res; 2020 Jul; 40(7):3925-3929. PubMed ID: 32620633
[TBL] [Abstract][Full Text] [Related]
60. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]